Autologous Hematopoietic Stem Cell Transplantation for Type 1 Diabetes
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2008
|
Resumo |
In this review, we present (1) the scientific basis for the use of high-dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for newly diagnosed type 1 diabetes (T1D); (2) an update of the clinical and laboratory outcome of 20 patients transplanted at the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, Brazil, and followed up to January/2008, including 4 relapses among 19 patients without previous ketoacidosis; (3) a commentary on criticisms to our article that appeared in four articles from the scientific literature; and (4) a discussion of the prospectives for cellular therapy for T1D. CNPq FAPESP FINEP CAPES FAEPA FUNDHERP |
Identificador |
Annals of the New York Academy of Sciences, v.1150, p.220-229, 2008 978-1-57331-733-7 0077-8923 http://producao.usp.br/handle/BDPI/25030 10.1196/annals.1447.048 |
Idioma(s) |
eng |
Publicador |
BLACKWELL PUBLISHING |
Relação |
Annals of the New York Academy of Sciences |
Direitos |
closedAccess Copyright BLACKWELL PUBLISHING |
Palavras-Chave | #type 1 diabetes #stem cell transplantation #high-dose immunosuppression #BONE-MARROW-TRANSPLANTATION #AUTOIMMUNE-DISEASES #ONSET #THERAPY #TOLERANCE #MELLITUS #MICE #Multidisciplinary Sciences |
Tipo |
article proceedings paper publishedVersion |